CA-NOVOTECH
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, Oesophageal Cancer — Global Clinical Trial Landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729339816/en/
This detailed analysis focuses on the extensive research and innovative treatments being developed to combat oesophageal cancer (OC), the seventh leading cause of cancer mortality worldwide, and the 11th most diagnosed cancer globally, with Asia accounting for nearly 70% of cases. Other areas of the report detail the research pipeline for OC, highlighting significant advancements in treatments aimed at improving patient outcomes as well as providing a robust analysis of the funding landscape from both public and private sources, which is currently led by entities based in China and the USA with approximately $5B USD in investment across those two nations.
The Novotech research analyst team provides these expert reports monthly, highlighting key metrics on the current status of specific diseases and outlining future trends that may impact the development of treatments. This is provided completely free of charge.
Key takeaways from the report:
Global Clinical Trial Activity:
- Since 2019, over 1,530 clinical trials for OC have been initiated globally, with the Asia-Pacific region (49%), North America (28%), and Europe (18%) leading the research efforts.
- Countries such as China, South Korea, Japan, and the USA are at the forefront of trial activities.
Rising Incidence:
- OC is the 11th most diagnosed cancer globally, with approximately 511,000 new cases and 445,400 deaths in 2022.
- By 2050, the annual incidence is projected to rise to 923,000 new cases, an 80.5% increase.
Innovative Treatment Approaches:
- The treatment landscape is shifting towards personalized medicine, with systemic therapies based on disease stage and molecular markers being recommended by the 2024 NCCN and 2022 ESMO Guidelines.
- The development pipeline is robust, with over 90 drugs in progress, including numerous Phase III trials focusing on diverse mechanisms of action.
Funding and Investment:
- Significant investment has been channeled into OC research, with China leading with $2.9 billion USD and the USA following with $2.1 billion USD.
- Other notable contributors include Switzerland, Singapore, Canada, and Japan.
Market Leaders:
- The report identifies key players in the OC treatment market, including Advanz Pharma Corp. Ltd, BeiGene Ltd., InnoKeys Pte. Ltd., and Simcere Pharmaceutical Group Ltd.
Strategic Insights:
- The report includes a SWOT analysis, demonstrating the effectiveness of current treatments in managing symptoms and improving quality of life, while also identifying areas where emerging techniques may offer improvements.
Download the report here
About Novotech
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729339816/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final Hearings on Aviator LLC’s IP Dispute to Be Heard in Georgian Court of Appeals on February 145.2.2025 15:25:00 CET | Press release
After reaching settlement with Flutter Entertainment Plc, Aviator LLC is continuing to pursue litigation against SPRIBE OU regarding IP infringement and legal ownership claims of the brand Aviator. Previously Georgia’s Court of First Instance has issued a judgment invalidating SPRIBE’s trademarks in Georgia, finding that SPRIBE registered disputed trademarks in bad faith and in breach of Aviator LLC’s copyrights. Factual Background The original Avaitor logo was created by the designer Mr. Giorgi Popiashvili in 2017 and was used by the land casino operator Aviator in Georgia since 2018. Casino Aviator was owned by Teumraz Ugulava and was operating under the premises of Stamba Hotel, also owned by him. The same logo was used for online roulette streaming on one of the biggest online gambling platforms in Georgia, called Adjarabet (www.adjarabet.com). At the time, this platform was also owned by Mr. Ugulava who was running Adjarabet under the company Aviator LLC, established in 2015. In 2
Tigo Energy Drive Towards Total Quality Solar Pays off With 1,000-System Green Glove Milestone5.2.2025 15:00:00 CET | Press release
Tigo Green Glove milestone covers installations on four continents, delivering comprehensive support to Commercial & Industrial (C&I) customers, and is expanding for residential installers. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” “Company”), a leading provider of intelligent solar and energy software solutions, today announced solar installers across four continents have enrolled more than 1,000 systems in the Tigo Green Glove program. Designed by Tigo as one of the main pillars to deliver Total Quality Solar (TQS) through comprehensive support at every stage of solar system deployment, the Green Glove program has rapidly become a vital resource for solar installers, driving faster design and deployment, higher-quality installations, inbuilt first-responder safety, and improved system performance and reliability. While nearly 70% of Green Glove engagements have come from the C&I sector, providing proactive quality assurance in larger, more complex solar installations, Tigo is now acti
Global CIO Study Reveals ROI Remains Greatest AI Adoption Barrier, Despite Three-Fold Spend Increase5.2.2025 15:00:00 CET | Press release
Lenovo-commissioned research reveals forty-two percent of global organizations plan to institutionalize Generative AI use casesThirty-seven percent of management remains skeptical toward AI Business leaders and IT decision-makers confirm AI use will reach mainstream levels of adoption as organizations devote a greater slice of their IT budgets to AI implementations, according to new IDC research commissioned by Lenovo. The new global 2025 CIO Playbook entitled It’s Time for AI-nomics, highlights AI spending expectations by IT decision-makers globally to nearly triple in 2025 compared with last year. But critical challenges include uncertain financial returns on these investments and gaps in organizational readiness. Proving ROI: The Greatest Barrier While most AI use cases have met business expectations, proving the return of these investments remains challenging—financial risk and uncertain ROI rank as the greatest barriers to AI adoption. This tension is magnified by a disconnect bet
Datassential Expands Global Menu and Limited-Time Offer Data Across Europe’s Big 5 Markets5.2.2025 14:30:00 CET | Press release
Datassential, the leading food and beverage intelligence platform connecting the dots between consumers and the industry, has announced the expansion of its cutting-edge global sales intelligence solution to include in-depth menu and limited-time offer (LTO) tracking across Europe’s Big 5 markets: France, Germany, Italy, Spain, and the U.K. This enhancement further solidifies Datassential’s position as the gold standard for empowering the foodservice ecosystem with actionable insights. With a foodservice prospecting platform tracking more than 11 million operators across 70+ countries and 100+ operator attributes, Datassential’s solution offers unparalleled tools to increase sales productivity and win rates. The addition of comprehensive menu data in these key European markets gives users access to deep insights, enabling smarter, data-driven menu recommendations tailored to operators' diverse needs. “Understanding global menus and limited-time offers has never been more critical for o
Celonis Research Unveils: 89% of Business Leaders say AI Without Process Intelligence Fails to Deliver Expected Results5.2.2025 10:00:00 CET | Press release
The vast majority of decision makers surveyed (89%) said AI needs to have the context of how their business runs to deliver the expected results.81% of respondents said their companies plan to use AI specifically to improve business processes in the next 12 months.The majority (58%) of leaders worry that process shortcomings may limit AI’s contribution to their business. Celonis, the global leader in Process Mining and Process Intelligence, today released survey findings that demonstrate widespread recognition that AI requires Process Intelligence to be effective and relevant for the business. With Celonis Process Intelligence, AI gains the context it needs to understand how a business runs and how to make it run better. The 2025 Process Optimization Report shows that the vast majority of enterprise leaders (89%) say it’s crucial that AI has the context of how their business runs if it is going to deliver meaningful results and increase operational efficiency. The majority (58%) worry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom